ArticleClinical drug investigation2021

Cost-effectiveness Analysis of Atezolizumab Plus Nab-Paclitaxel for Advanced PD-L1 Positive Triple-Negative Breast Cancer in Japan.

Yugo Chisaki et al.PubMed ↗Publisher ↗

No numbers read from the abstract.